

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Youngman *et al.*

Confirmation No.: 1718

Serial No.: 10/538,183

Group Art Unit: 1625

Filed: June 9, 2005

Examiner: *(not yet assigned)*

For: INDANE COMPOUNDS AS CCR5 ANTAGONISTS

---

Office of Initial Patent Examination  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**REQUEST FOR CORRECTED FILING RECEIPT**

1. Attached is a copy of the Official Filing Receipt received from the PTO in the above application for which issuance of a second Corrected Filing Receipt is respectfully requested.
2. There is an error with respect to the following data, which is:

☒ **incorrectly entered**                      and/or                      ☐ **omitted.**

<b>Error in</b>	<b>Correct data</b>
1. <input type="checkbox"/> Applicant's name	1. -
2. <input checked="" type="checkbox"/> Applicant's address	2. Hanbiao Yang, <u>Stanford</u> , CA
3. <input type="checkbox"/> Title	3. -
4. <input type="checkbox"/> Filing date	4. -
5. <input type="checkbox"/> Serial Number	5. -
6. <input type="checkbox"/> Foreign/PCT Application Re:	6. -
7. <input type="checkbox"/> Other:	7. -

Respectfully submitted,



Bonnie L. Deppenbrock  
Attorney for Applicant  
Registration No. 28,209

Date: 29 August 2007  
Customer No. 28347  
GlaxoSmithKline  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1577  
Facsimile: (919) 483-7988

**ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES  
PATENT & TRADEMARK OFFICE ON August 29, 2007.**



# UNITED STATES PATENT AND TRADEMARK OFFICE

# COPY

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371(c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLMS	IND CLMS
✓ 10/538,183	✓ 06/09/2005	1625	✓ 1850	✓ PU4963USw	✓ 34	✓ 2

CONFIRMATION NO. 1718

CORRECTED FILING RECEIPT



\*OC000000025366360\*

23347  
GLAXOSMITHKLINE  
CORPORATE INTELLECTUAL PROPERTY, MAI B475  
FIVE MOORE DR., PO BOX 13398  
RESEARCH TRIANGLE PARK, NC 27709-3398

Date Mailed: 08/14/2007

Receipt is acknowledged of this nonprovisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

- ✓ Michael Youngman, Durham, NC;
- ✓ Wieslaw Mieczyslaw Kazmierski, Durham, NC;
- X Hanbiao Yang (Stanford, CA);
- ✓ Christopher Joseph Aquino, Durham, NC;

STANFORD, CA

RECEIVED  
AUG 16 2007

GLAXOSMITHKLINE  
CIP/RTF

Power of Attorney: The patent practitioners associated with Customer Number 23347.

## Domestic Priority data as claimed by applicant

- This application is a 371 of PCT/US03/39975 12/12/2003
- ✓ which claims benefit of 60/433,378 12/13/2002

## Foreign Applications

If Required, Foreign Filing License Granted: 08/14/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is  
**US10/538,183**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

## Title

- Indane compounds as ccr5 antagonists